Who Owns Scribe Therapeutics Stock?
NASDAQ: SCTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Pre-market: 19.50 +1.40%
Ownership breakdown
- Held by institutions
- 54.46%
- Held by insiders
- 10.70%
- Institutional holders
- 19
- Institutions 54.5%
- Insiders 10.7%
- Public and other 34.8%
Who owns Scribe Therapeutics stock?
Institutional investors own about 54.5% of Scribe Therapeutics's shares, spread across 19 institutions that file 13F reports. That level of institutional ownership is moderate. Insiders, including executives, directors and large founding shareholders, hold 10.70% of SCTX.
Summary generated from market data by MetaCap's automated system. Methodology
Top mutual fund and ETF holders of SCTX
| Fund | Shares | % Held |
|---|---|---|
| ARK ETF Trust-ARK Genomic Revolution ETF | 411.34K | 2.17% |
| Franklin Strategic Series-Franklin Biotechnology Discovery Fund | 135.57K | 0.72% |
| Fidelity Rutland Square TRT II-Strategic Advisers U.S. Total Stock Fd. | 138 | 0.00% |
Frequently asked questions
What percentage of Scribe Therapeutics is owned by institutions?
Institutions own about 54.5% of SCTX shares and 61.0% of the public float.
How much of Scribe Therapeutics do insiders own?
Insiders, such as officers and directors, own about 10.70% of SCTX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.